IL1A and rheumatoid arthritis: Treatment of RA with IL-1 pathway inhibitors has achieved moderate clinical success and is currently prescribed to limit the progression of joint damage in individuals with moderate to severe RA (Arend et al., 1998; Bresnihan et al., 1998).